Figure 1 | Experimental & Molecular Medicine

Figure 1

From: PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury

Figure 1

Rosiglitazone (RSG) changes vascular smooth muscle cell (VSMC) morphology via the protein kinase G (PKG) pathway. (a–d) Representative images of morphologic changes of VSMCs treated with various chemicals. Platelet-derived growth factor (PDGF) treatment changed VSMC morphology from a spindle-shaped contractile form to an epitheloid synthetic form. However, RSG treatment blocked the change of VSMC morphology induced by PDGF treatment. In addition, PKG inhibitor (8-Rp-cPT-cGMP) reversed the effect of RSG, suggesting that the effect of RSG on VSMC morphology is mediated through a PKG pathway. Scale bar=100 μm. (e) Quantitative graph of the ratio of pole-to-pole length (long axis/short axis) in each group. *P<0.05 vs vehicle. **P<0.05 vs PDGF+RSG, n=4. Inset figures are magnified forms of original figures.

Back to article page